Logo image of VET

VERMILION ENERGY INC (VET) Stock Fundamental Analysis

NYSE:VET - New York Stock Exchange, Inc. - CA9237251058 - Common Stock - Currency: USD

7.51  -0.32 (-4.09%)

After market: 7.5104 +0 (+0.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VET. VET was compared to 208 industry peers in the Oil, Gas & Consumable Fuels industry. There are concerns on the financial health of VET while its profitability can be described as average. VET does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

VET had positive earnings in the past year.
In the past year VET had a positive cash flow from operations.
In multiple years VET reported negative net income over the last 5 years.
VET had a positive operating cash flow in each of the past 5 years.
VET Yearly Net Income VS EBIT VS OCF VS FCFVET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B

1.2 Ratios

VET has a Return On Assets of -0.48%. This is in the lower half of the industry: VET underperforms 69.23% of its industry peers.
VET has a Return On Equity of -1.18%. This is in the lower half of the industry: VET underperforms 67.79% of its industry peers.
VET has a worse Return On Invested Capital (3.37%) than 66.35% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VET is significantly below the industry average of 23.63%.
The 3 year average ROIC (10.72%) for VET is well above the current ROIC(3.37%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -0.48%
ROE -1.18%
ROIC 3.37%
ROA(3y)4.74%
ROA(5y)-0.65%
ROE(3y)9.7%
ROE(5y)-15.85%
ROIC(3y)10.72%
ROIC(5y)N/A
VET Yearly ROA, ROE, ROICVET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

With a Operating Margin value of 14.04%, VET perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
In the last couple of years the Operating Margin of VET has grown nicely.
With a decent Gross Margin value of 67.37%, VET is doing good in the industry, outperforming 75.96% of the companies in the same industry.
In the last couple of years the Gross Margin of VET has remained more or less at the same level.
Industry RankSector Rank
OM 14.04%
PM (TTM) N/A
GM 67.37%
OM growth 3Y-29.16%
OM growth 5Y2.82%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y0.95%
VET Yearly Profit, Operating, Gross MarginsVET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

VET has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for VET has been reduced compared to 1 year ago.
Compared to 5 years ago, VET has less shares outstanding
The debt/assets ratio for VET is higher compared to a year ago.
VET Yearly Shares OutstandingVET Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
VET Yearly Total Debt VS Total AssetsVET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

VET has an Altman-Z score of 0.34. This is a bad value and indicates that VET is not financially healthy and even has some risk of bankruptcy.
VET has a worse Altman-Z score (0.34) than 65.87% of its industry peers.
A Debt/Equity ratio of 0.67 indicates that VET is somewhat dependend on debt financing.
The Debt to Equity ratio of VET (0.67) is worse than 60.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Altman-Z 0.34
ROIC/WACC0.37
WACC9.23%
VET Yearly LT Debt VS Equity VS FCFVET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

VET has a Current Ratio of 0.71. This is a bad value and indicates that VET is not financially healthy enough and could expect problems in meeting its short term obligations.
VET has a worse Current ratio (0.71) than 74.04% of its industry peers.
VET has a Quick Ratio of 0.71. This is a bad value and indicates that VET is not financially healthy enough and could expect problems in meeting its short term obligations.
VET has a Quick ratio of 0.64. This is in the lower half of the industry: VET underperforms 73.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.71
Quick Ratio 0.64
VET Yearly Current Assets VS Current LiabilitesVET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 100.69% over the past year.
Looking at the last year, VET shows a decrease in Revenue. The Revenue has decreased by -5.56% in the last year.
VET shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.65% yearly.
EPS 1Y (TTM)100.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.14%
Revenue 1Y (TTM)-5.56%
Revenue growth 3Y-2.42%
Revenue growth 5Y1.65%
Sales Q2Q%-4.37%

3.2 Future

The Earnings Per Share is expected to decrease by -71.57% on average over the next years. This is quite bad
VET is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.14% yearly.
EPS Next Y188.65%
EPS Next 2Y-88.02%
EPS Next 3Y-71.57%
EPS Next 5YN/A
Revenue Next Year11.34%
Revenue Next 2Y-8.26%
Revenue Next 3Y1.22%
Revenue Next 5Y3.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VET Yearly Revenue VS EstimatesVET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B
VET Yearly EPS VS EstimatesVET Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 250.33, VET can be considered very expensive at the moment.
Based on the Price/Earnings ratio, VET is valued a bit more expensive than the industry average as 69.71% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of VET to the average of the S&P500 Index (26.48), we can say VET is valued expensively.
VET is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 250.33
Fwd PE N/A
VET Price Earnings VS Forward Price EarningsVET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, VET is valued cheaper than 82.21% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.66
VET Per share dataVET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A cheap valuation may be justified as VET's earnings are expected to decrease with -71.57% in the coming years.
PEG (NY)1.33
PEG (5Y)N/A
EPS Next 2Y-88.02%
EPS Next 3Y-71.57%

More info and screens

5

5. Dividend

5.1 Amount

VET has a Yearly Dividend Yield of 4.66%, which is a nice return.
Compared to an average industry Dividend Yield of 6.32, VET pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.39, VET pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.66%

5.2 History

The dividend of VET decreases each year by -28.87%.
VET has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of VET decreased in the last 3 years.
Dividend Growth(5Y)-28.87%
Div Incr Years2
Div Non Decr Years2
VET Yearly Dividends per shareVET Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of VET are negative and hence is the payout ratio. VET will probably not be able to sustain this dividend level.
The Dividend Rate of VET has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP-220.96%
EPS Next 2Y-88.02%
EPS Next 3Y-71.57%
VET Yearly Income VS Free CF VS DividendVET Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B -1.5B

More info and screens

VERMILION ENERGY INC

NYSE:VET (8/8/2025, 8:10:59 PM)

After market: 7.5104 +0 (+0.01%)

7.51

-0.32 (-4.09%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners50.53%
Inst Owner Change-1.19%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap1.16B
Analysts72
Price Target9.87 (31.42%)
Short Float %10.2%
Short Ratio11.45
Dividend
Industry RankSector Rank
Dividend Yield 4.66%
Yearly Dividend0.34
Dividend Growth(5Y)-28.87%
DP-220.96%
Div Incr Years2
Div Non Decr Years2
Ex-Date06-30 2025-06-30 (0.13)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.33%
Min EPS beat(2)-124.5%
Max EPS beat(2)-58.17%
EPS beat(4)0
Avg EPS beat(4)-114.29%
Min EPS beat(4)-247.1%
Max EPS beat(4)-27.39%
EPS beat(8)1
Avg EPS beat(8)-161.1%
EPS beat(12)4
Avg EPS beat(12)1443.31%
EPS beat(16)6
Avg EPS beat(16)1434.15%
Revenue beat(2)0
Avg Revenue beat(2)-5.52%
Min Revenue beat(2)-6.7%
Max Revenue beat(2)-4.34%
Revenue beat(4)0
Avg Revenue beat(4)-7.73%
Min Revenue beat(4)-11.51%
Max Revenue beat(4)-4.34%
Revenue beat(8)0
Avg Revenue beat(8)-10.72%
Revenue beat(12)2
Avg Revenue beat(12)-3.92%
Revenue beat(16)6
Avg Revenue beat(16)4.54%
PT rev (1m)-0.86%
PT rev (3m)-9.96%
EPS NQ rev (1m)33.33%
EPS NQ rev (3m)-433.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)6.58%
Revenue NQ rev (3m)-2.69%
Revenue NY rev (1m)-8.38%
Revenue NY rev (3m)-8.38%
Valuation
Industry RankSector Rank
PE 250.33
Fwd PE N/A
P/S 0.82
P/FCF N/A
P/OCF 1.78
P/B 0.55
P/tB 0.55
EV/EBITDA 3.66
EPS(TTM)0.03
EY0.4%
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)4.22
OCFY56.25%
SpS9.14
BVpS13.62
TBVpS13.62
PEG (NY)1.33
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.48%
ROE -1.18%
ROCE 4.27%
ROIC 3.37%
ROICexc 3.38%
ROICexgc 3.38%
OM 14.04%
PM (TTM) N/A
GM 67.37%
FCFM N/A
ROA(3y)4.74%
ROA(5y)-0.65%
ROE(3y)9.7%
ROE(5y)-15.85%
ROIC(3y)10.72%
ROIC(5y)N/A
ROICexc(3y)10.81%
ROICexc(5y)N/A
ROICexgc(3y)10.81%
ROICexgc(5y)N/A
ROCE(3y)13.57%
ROCE(5y)N/A
ROICexcg growth 3Y-31.83%
ROICexcg growth 5Y4.7%
ROICexc growth 3Y-31.83%
ROICexc growth 5Y4.7%
OM growth 3Y-29.16%
OM growth 5Y2.82%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.52%
GM growth 5Y0.95%
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA 2.03
Cap/Depr 251.24%
Cap/Sales 88.48%
Interest Coverage 2.91
Cash Conversion 93.81%
Profit Quality N/A
Current Ratio 0.71
Quick Ratio 0.64
Altman-Z 0.34
F-Score5
WACC9.23%
ROIC/WACC0.37
Cap/Depr(3y)126.62%
Cap/Depr(5y)107.23%
Cap/Sales(3y)33.7%
Cap/Sales(5y)32.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.14%
EPS Next Y188.65%
EPS Next 2Y-88.02%
EPS Next 3Y-71.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.56%
Revenue growth 3Y-2.42%
Revenue growth 5Y1.65%
Sales Q2Q%-4.37%
Revenue Next Year11.34%
Revenue Next 2Y-8.26%
Revenue Next 3Y1.22%
Revenue Next 5Y3.14%
EBIT growth 1Y4.97%
EBIT growth 3Y-30.87%
EBIT growth 5Y4.51%
EBIT Next Year102.66%
EBIT Next 3Y12.45%
EBIT Next 5Y15.47%
FCF growth 1Y-235.66%
FCF growth 3Y0.4%
FCF growth 5Y4.86%
OCF growth 1Y-51.99%
OCF growth 3Y5.06%
OCF growth 5Y3.28%